EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeting Lung Cancer Stem Cells with Trimebutine: Synergistic Antitumor Activity in Combination with Cisplatin

JiHye Seo, Heejin Lee, Dong Kyu Choi, Young-Kyu Kim, Somin Woo, Changkyu Lee, Jeong In Choi iD, Ge Jiang, Bae Jun Oh, Dong-Seok Lee iD, Sang-Hyun Min

International Journal of Molecular Sciences · 2026

DOI: 10.3390/ijms27188211 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von JiHye Seo und 10 weiteren Autor:innen. Beteiligte Einrichtung: School of Life Sciences & Biotechnology, College of Natural Sciences, Kyungpook National University, Daegu 41566, Republic of Korea. Hauptthemen laut MEDLINE: Cisplatin, Neoplastic Stem Cells, Lung Neoplasms, Trimebutine. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea, Daegu ANCHOR Center, Ministry of Education.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lung cancer recurrence and therapeutic resistance are driven by cancer stem cells (CSCs), yet clinically available CSC-targeted therapies remain lacking. To identify actionable anti-CSC agents, we screened 1018 FDA-approved drugs using a 3D sphere culture system enriching lung CSC-like cells. Trimebutine, a gastrointestinal motility regulator targeting G-protein-coupled receptors (GPCRs), was identified as a potent agent with over 49.5-fold higher selectivity toward lung CSC-like cells (SI > 49.55) compared with standard therapies such as cisplatin (SI = 1.39) and gefitinib (SI = 1.00). In H460-SP spheres, trimebutine markedly impaired sphere-forming capacity, reduced cell viability, and downregulated key CSC surface markers (CD133, CD44) alongside stemness regulators (c-MYC, EpCAM, BMI1, OCT3/4, NANOG, SOX2, SMAD3). Mechanistically, trimebutine suppressed overexpressed calcium and potassium channels (CACNA1F, CACNA1B, CACNA1E, CACNA1H, KCNH2), attenuating downstream YAP/TAZ–TEAD signaling within the Hippo pathway to trigger apoptosis. In combination with cisplatin, trimebutine exhibited strong synergistic efficacy (Chou–Talalay combination index, CI = 0.015–0.228) in H460-SP spheres and patient-derived lung tumor organoids, suppressing cell viability, stemness marker suppression, and apoptotic cleavage of caspase-3 and PARP compared to monotherapies. Overall, trimebutine targets lung CSC populations by disrupting GPCR–ion channel–Hippo signaling crosstalk, providing a strong preclinical rationale for trimebutine–cisplatin combination strategies to overcome drug resistance and recurrence in lung cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CisplatinNeoplastic Stem CellsLung NeoplasmsTrimebutineAntineoplastic AgentsHumansDrug SynergismCell Line, TumorAnimalsCell SurvivalSpheroids, CellularApoptosisSignal Transduction

Stichwörter der Autor:innen

G protein–coupled receptoranticancerdrug resistancelung cancermetastasissynergistic effect

Substanzen

CisplatinTrimebutineAntineoplastic Agents

Autor:innen und Institutionen

  • School of Life Sciences & Biotechnology, College of Natural Sciences, Kyungpook National University, Daegu 41566, Republic of Korea.
  • Daegu ANCHOR Center, Kyungpook National University, Daegu 41566, Republic of Korea.
  • New Drug Development Center, Daegu-Gyeongbuk Medical Innovation Foundation (K-MEDI Hub), Daegu 41061, Republic of Korea.
  • BK21 FOUR KNU Creative BioResearch Group, School of Life Science and Biotechnology, Kyungpook National University, Daegu 41566, Republic of Korea.
  • Graduate School of Pharmacy, Kyungpook National University, Daegu 41566, Republic of Korea.
  • BK21 Infectious Disease Healthcare Program, Kyungpook National University, Daegu 41566, Republic of Korea.

ORCID-Profile: Jeong In Choi, Dong-Seok Lee

Förderung

  • National Research Foundation of Korea
  • Daegu ANCHOR Center
  • Ministry of Education

Zitieren

APA

Seo, J., Lee, H., Choi, D. K., Kim, Y. K., Woo, S., Lee, C., Choi, J. I., Jiang, G., Oh, B. J., Lee, D. S., & Min, S. H. (2026). Targeting Lung Cancer Stem Cells with Trimebutine: Synergistic Antitumor Activity in Combination with Cisplatin. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27188211

Vancouver

Seo J, Lee H, Choi DK, Kim YK, Woo S, Lee C, et al. Targeting Lung Cancer Stem Cells with Trimebutine: Synergistic Antitumor Activity in Combination with Cisplatin. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27188211

BibTeX
@article{Seo2026,
  author = {Seo, JiHye and Lee, Heejin and Choi, Dong Kyu and Kim, Young-Kyu and Woo, Somin and Lee, Changkyu and Choi, Jeong In and Jiang, Ge and Oh, Bae Jun and Lee, Dong-Seok and Min, Sang-Hyun},
  title = {Targeting Lung Cancer Stem Cells with Trimebutine: Synergistic Antitumor Activity in Combination with Cisplatin},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  doi = {10.3390/ijms27188211}
}
Kostenlos starten →